



2019

**BLOOM BURTON & CO.
HEALTHCARE INVESTOR
CONFERENCE**

APRIL 30 - MAY 1

TORONTO, ONTARIO



Bloom Burton & Co. exists to accelerate returns in the healthcare sector for both companies and investors. There is no greater illustration of the power of our platform than this conference, which has grown into Canada's flagship healthcare investment and networking event over the past eight years.

welcome

Bloom Burton & Co. and its affiliates continue to expand a talented and dedicated team to provide important services to accelerate the growth of companies and returns for investors. We offer investment banking services such as capital raising, M&A advisory, equity research, sales, trading and monetization planning, our scientific/business advisory work. We have expanded our direct investment capabilities by offering equity and debt funds to interested investors and have internalized the management of those funds. Finally, entirely new companies we have founded and launched, such as Triumvira Immunologics, Appili Therapeutics, Grey Wolf Animal Health and Satellos Bioscience, will present at this very conference.

We had our second black-tie Bloom Burton Award Gala last September and it has now cemented itself as the preeminent award to celebrate each year's most important contributor in the Canadian healthcare sector. We hope to see you all at the third annual Bloom Burton Award Gala on September 26, 2019. Our three finalists for the 2019 award will be announced this week!

We are humbled to serve as the central catalyst for our industry and so proud of our team, who work tirelessly to serve our clients. We strive to produce exceptional deliverables and outcomes and we are here for you as you make new connections and plan for the success of the healthcare sector in Canada.

Have a wonderful conference!

Brian and Jolyon and the entire team

contents

04

AGENDA

08

COMPANY PROFILES

42

KEYNOTE SPEAKER

44

PANELISTS

50

SPONSORS

64

LOGISTICS

BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE

april 30th - may 1st



about

The Bloom Burton & Co. Healthcare Investor Conference attracts Canadian, U.S. and International investors who are interested in the latest developments in Canadian healthcare companies. Investors have the opportunity to obtain corporate updates from presenting companies, and participate in our 1-on-1 meeting system with company management.

agenda

april 30th

8:30 am **REGISTRATION | OPENING REMARKS | TSX MARKET OPEN**

HALL CD

HALL B

HALL A

9:30 am

Knight Therapeutics

Trillium Therapeutics

Newtopia

10:00 am

Cipher Pharmaceuticals

Zymeworks

Intellijoint Surgical

10:30 am

Medicure

Aptose Biosciences

Conavi Medical

11:00 am

Medexus

Oncolytics Biotech

Precision NanoSystems

11:30 am

Highland Therapeutics

Aurinia Pharmaceuticals

7D Surgical

12:00 pm

INVESTOR PANEL: INVESTING IN COMMERCIAL-STAGE HEALTHCARE COMPANIES

Panelists: Sumner Anderson | Cecilia Gonzalo | Adele Oliva | Chris York | Jason Wild

1:30 pm

HLS Therapeutics

Antibe Therapeutics

Titan Medical

2:00 pm

Nuvo Pharmaceuticals

Medicenna Therapeutics

Synaptive Medical

2:30 pm

Correvio Pharma

IntelGenx

Opsens

3:00 pm

Crescita Therapeutics

Avivagen

TSO3

3:30 pm

CRH Medical

Appili Pharmaceuticals

Profound Medical

4:00 pm

Centric Health

Microbix Biosystems

Exact Imaging

5:00 pm

BBHC COCKTAIL RECEPTION | STEAM WHISTLE BREWING

agenda

may 1st

8:30 am REGISTRATION | KEYNOTE ADDRESS: BRAD LONCAR

HALL CD

HALL B

HALL A

9:30 am

BioSyent Pharma

BELLUS Health

Think Research

10:00 am

Acerus Pharmaceuticals

Xenon Pharmaceuticals

Dot Health

10:30 am

Greenbrook TMS

ESSA Pharma

Interface Biologics

11:00 am

Hamilton Thorne

IMV

LED Medical Diagnostics

11:30 am

Shoppers Drug Mart

Fusion Pharmaceuticals

Kneat

12:00 pm INVESTOR PANEL: INVESTING IN R&D-STAGE HEALTHCARE COMPANIES

Panelists: Jerel Davis | Arjun Goyal | Ting Jia | Doron Junger | Maha Katabi

1:30 pm

STEMCELL Technologies

Endoceutics

Mimi's Rock

2:00 pm

ImmunoPrecise Antibodies

Repare Therapeutics

Grey Wolf Animal Health

2:30 pm

Viemed

Satellos Bioscience

Aequus Pharmaceuticals

3:00 pm

NeuPath Health

Triumvira Immunologics

Searchlight Pharma

3:30 pm

WELL Health Technologies

AbCellera

Methapharm

4:00 pm

Sernova

Eupraxia Pharmaceuticals

Valeo Pharma



presenting companies

The Bloom Burton & Co. Healthcare Investor Conference hosts 66 of Canada's premier publicly-traded and venture-backed private companies together with the most promising pre-venture companies in the healthcare industry.





66 presenting companies



29 private companies

37 public companies



Research & Development

Specialty Pharma

Medical Technology

Healthcare IT

Healthcare Services

Research Tools

PRESENTING COMPANIES



7D Surgical

7D Surgical is a privately-owned Toronto based company that develops advanced optical technologies and machine vision-based registration algorithms to improve surgical workflow and patient care. 7D Surgical's flagship FDA 510(k)-cleared and Health Canada approved MvIGS system delivers profound improvement to surgical workflows in spine and cranial surgery. The underlying technology provides the promise of similar future advancements for other surgical specialties.

Tuesday, April 30th
11:30am; Hall A

Private



AbCellera

AbCellera is a privately held company that engages in partnerships to discover and develop next-generation therapeutic antibodies. AbCellera's single-cell platform integrates end-to-end capabilities for therapeutic antibody discovery through a unique combination of technologies including proprietary immunizations, microfluidics, high-throughput imaging, genomics, deep computation, artificial intelligence, and laboratory automation. Ultra-deep screening of single B cells allows unprecedented access to natural immune responses, enabling rapid isolation of large and diverse panels of high-quality lead antibodies from any species, including humans.

Wednesday, May 1st
3:30pm; Hall B

Private



Acerus Pharmaceuticals

Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve patient experience, with a primary focus in the field of men's and women's health. The Company commercializes its products via its own salesforce in Canada, and through a global network of licensed distributors in the U.S. and other territories.

Wednesday, May 1st

10:00am; Hall CD

TSX: ASP



Aequus Pharmaceuticals

Aequus Pharmaceuticals Inc. is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its pipeline to include several commercial products in ophthalmology and transplant, and a development stage pipeline in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. As a complement to its focus in neurology, our most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates worldwide.

Wednesday, May 1st

2:30pm; Hall A

TSX-V: AQS

PRESENTING COMPANIES



Antibe Therapeutics

Antibe develops safer medicines for pain and inflammation. Antibe's technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe's lead drug ATB-346 targets the global need for a safer drug for chronic pain and inflammation. ATB-352, the second drug in Antibe's pipeline, targets the urgent global need for a safer, non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. Antibe's subsidiary, Citagenix Inc. ("Citagenix"), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces.

Tuesday, April 30th

1:30pm; Hall B

TSX-V: ATE



Appili Therapeutics

Appili Therapeutics, Inc., was founded to advance the global fight against infectious disease by matching clearly-defined patient needs with drug development programs that provide solutions to existing challenges patients, doctors and society face in this challenging disease space. Balancing near-to-market product candidates with higher-risk but potentially transformative early-stage programs, Appili's growing pipeline includes assets being developed by Appili as well as an active licensing program. ATI-1501 employs Appili's proprietary, taste-masked, oral-suspension technology with metronidazole for the growing number of pediatric and elderly patients with difficulty swallowing. ATI-1503 is a drug discovery program aimed at generating negamycin analogue candidates, a novel class of antibiotics with broad-spectrum activity against Gram-negative bacteria.

Tuesday, April 30th

3:30pm; Hall B

Private



Aptose Biosciences

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. APTO-253, the only clinical stage agent that directly targets the MYC oncogene and inhibits its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk MDS.

Tuesday, April 30th

10:30am; Hall B

TSX: APS NASDAQ: APTO



Aurinia Pharmaceuticals

Aurinia Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The company is currently developing an investigational drug, for the treatment of Lupus Nephritis, Focal Segmental Glomerulosclerosis and Dry Eye Syndrome. The company is headquartered in Victoria, British Columbia and focuses its development efforts globally.

Tuesday, April 30th

11:30am; Hall B

TSX: AUP NASDAQ: AUPH

PRESENTING COMPANIES

Avivagen

Avivagen

Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island.

Tuesday, April 30th
3:00pm; Hall B

TSX-V: VIV



BELLUS Health

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need. The Company's lead drug candidate is BLU-5937 being developed for the treatment of chronic cough. BLU-5937, a highly selective P2X3 antagonist, has the potential to be a best-in-class therapeutic for chronic cough patients who do not respond to current therapies. Chronic cough is a cough that lasts more than eight weeks and is associated with significant adverse social, psychosocial and physical effects on quality of life. A recent commercial assessment performed by Bluestar BioAdvisors (formerly known as Torrey Insights) on behalf of the Company concluded that, in the United States alone, more than 26 million adults have chronic cough and more than 2.6 million of these patients suffer from refractory chronic cough lasting for more than a year.

Wednesday, May 1st
9:30am; Hall B

TSX: BLU



BioSyent Pharma

BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.

Wednesday, May 1st
9:30am; Hall CD

TSX-V: RX



Centric Health

Centric Health's vision is to be the leading independent provider of pharmacy and other healthcare services to Canadian seniors. The Company aspires to be world renowned for delivering the highest levels of quality care and outcomes, innovative solutions and value to seniors, patients, clients and stakeholders. Centric Health has two main operating segments, its Specialty Pharmacy division and its Surgical and Medical Centres division. With national networks of facilities in each of its businesses, deep knowledge and experience of healthcare delivery and extensive, trusted relationships with payers, physicians, and government agencies, the Company is uniquely positioned to address current and future healthcare needs in growing markets as the Canadian healthcare industry goes through a major transformation over the medium to long term.

Tuesday, April 30th
4:00pm; Hall CD

TSX: CHH

PRESENTING COMPANIES



Cipher Pharmaceuticals

Cipher is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. Cipher is focused on a three-pronged growth strategy - including acquisitions, in-licensing, and selective investments in drug development - to assemble a broad portfolio of prescription products that serve unmet medical needs.

Tuesday, April 30th

10:00am; Hall CD

TSX: CPH



Conavi Medical

Conavi Medical is a commercial-stage medical device company that develops and sells image guidance technologies for use in minimally invasive procedures with an initial focus in cardiology. The company's primary product offering is an intravascular imaging system, which combines catheter-based intravascular ultrasound (IVUS) and optical coherence tomography (OCT) onto a single catheter for use in coronary arteries. This system is the first technology to combine co-linear and co-registered IVUS and OCT, and the cost, image quality and catheter-size are comparable to standalone systems.

Tuesday, April 30th

10:30am; Hall A

Private

correvio

Correvio Pharma

Correvio Pharma Corp. is a specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients. With a commercial presence and distribution network covering over 60 countries worldwide, Correvio develops, acquires and commercializes brands for the in-hospital, acute care market segment. The Company's portfolio of approved and marketed brands includes: Xydalba™ (dalbavancin hydrochloride), Zevtera®/Mabelio® (ceftobiprole medocartil sodium), Brinavess® (vernakalant IV), Aggrastat® (tirofiban hydrochloride) and Esmocard® and Esmocard Lyo® (esmolol hydrochloride).

Tuesday, April 30th

2:30pm; Hall CD

TSX: CORV NASDAQ: CORV

CRESCITA THERAPEUTICS

Crescita Therapeutics

Crescita is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin.

Tuesday, April 30th

3:00pm; Hall CD

TSX: CTX

PRESENTING COMPANIES



CRH Medical

CRH Medical Corporation is a North American company focused on providing gastroenterologists throughout the United States with innovative services and products for the treatment of gastrointestinal diseases. In 2014, CRH became a full-service gastroenterology anesthesia company that provides anesthesia services for patients undergoing endoscopic procedures in ambulatory surgical centers. To date, CRH has completed 21 anesthesia acquisitions. CRH now serves 47 ambulatory surgical centers in eleven states and performs approximately 320,000 procedures annually. In addition, CRH owns the CRH O'Regan System, a single-use, disposable, hemorrhoid banding technology that is safe and highly effective in treating all grades of hemorrhoids.

Tuesday, April 30th

3:30pm; Hall CD

TSX: CRH NYSE: CRHM

dot health

Dot Health

Dot Health's mission is to empower all Canadians to better manage and understand their health by getting easy and convenient access to their medical records. Dot Health was incorporated in August 2016, closed a VC round in October 2017, and released its first product to market in November 2017. Through a convenient mobile app, Canadians can now request, receive, download, and share their personal health records, from any health care provider. Dot Health aims to make health data "liquid," while prioritizing privacy and security, increasing transparency and enabling secure data transfer between patients and providers. As we empower more Canadians with access to health data, we are also working to increase health literacy: we run all data through an optical character recognition (OCR) engine that converts records to a user-friendly format and enables the user to quickly search, filter, and pull out key pieces of information. When patients have access to their health care data, there are reduced health provider visits, improved patient outcomes, and increased adherence to care plans.

Wednesday, May 1st

10:00am; Hall A

Private



Endoceutics

Endoceutics is a private pharmaceutical company operating in the field of women's health and hormone-sensitive cancer prevention and treatment. Following approval by the US FDA of Intrarosa® in November 2016 for the treatment of dyspareunia, a symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause, Endoceutics has focused its efforts on developing non estrogen-based therapies for sexual dysfunction and the other symptoms of menopause. Hormonal therapies for breast, uterine and prostate cancer, male hypogonadism as well as endometriosis are also under development. Endoceutics has five Phase III product candidates addressing large market opportunities and two Phase I/II product candidates.

Wednesday, May 1st

1:30pm; Hall B

Private



ESSA Pharma

ESSA is a pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer ("CRPC") in patients whose disease is progressing despite treatment with current therapies. ESSA believes that its proprietary compounds can significantly expand the interval of time in which patients suffering from CRPC can benefit from hormone-based therapies, by disrupting the androgen receptor ("AR") signaling pathway that drives prostate cancer growth and by preventing AR transcriptional activity by binding selectively to the N-terminal domain ("NTD") of the AR. A functional NTD is essential for transactivation of the AR. In preclinical studies, blocking the NTD has demonstrated the capability to overcome the known AR-dependent mechanisms of CRPC.

Wednesday, May 1st

9:30am; Hall B

TSX-V: EPI NASDAQ: EPIX

PRESENTING COMPANIES



Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc. is a Canadian privately owned specialty pharmaceutical company that leverages its proprietary technologies to optimize drug delivery. We are currently advancing a portfolio of injectable drug candidates that have the potential to provide sustained drug release over a variety of indications.

Wednesday, May 1st
4:00pm; Hall B

Private



Exact Imaging

Exact Imaging is the world's leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Exact Imaging's ExactVu™ micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and is an extension of the current urological workflow. Using the Exact Imaging platform, urologists are able to visualize areas of interest in the prostate and specifically target biopsies at those areas. For those cases where MRI might assist (i.e., prior negative biopsies), the FusionVu™ micro-US/MRI fusion application operates on the ExactVu micro-ultrasound platform and facilitates MRI fusion-based targeting. The ExactVu micro-ultrasound system including the FusionVu application have received regulatory approval in the European Union (CE Mark), the United States (FDA 510(k)) and Canada (Health Canada medical device license).

Tuesday, April 30th
4:00pm; Hall A

Private



Fusion Pharmaceuticals

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company located in Hamilton, Ontario, Canada and Boston, MA, focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules, via its proprietary Fast-Clear™ Technology Platform, to create highly effective therapeutics. In addition to its lead program, FPI-1434, which had its first patient dosed in a Phase I trial in February 2019, Fusion is expanding its pipeline of products through a proprietary protein discovery platform, in-licensing targeting molecules, and forming new strategic partnerships.

Wednesday, May 1st

11:30am; Hall B

Private



Greenbrook TMS

Operating through 60 Company-operated treatment centers, Greenbrook is a leading provider of TMS, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 200,000 TMS treatments to over 5,700 patients struggling with depression.

Wednesday, May 1st

10:30am; Hall CD

Private

PRESENTING COMPANIES



Grey Wolf Animal Health

Grey Wolf was created in 2015 to identify and bring to market products that meet the underserved needs of veterinarians and pet owners across Canada and around the world.

Wednesday, May 1st
2:00pm; Hall A

Private



Hamilton Thorne

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne's customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

Wednesday, May 1st
11:00am; Hall CD

TSX-V: HTL



Highland Therapeutics

Highland Therapeutics Inc. is a pharmaceutical company that is focused on the commercialization of innovative pharmaceutical brands in the U.S. Highland Therapeutics Inc. is a client of MaRS Discovery District's Health Venture Services group, which provides advisory services, connections to talent, customer & capital networks, and market intelligence to high-impact, Ontario-based life sciences ventures, helping them commercialize their ideas and build globally competitive companies.

Tuesday, April 30th

11:30am; Hall CD

Private



HLS Therapeutics Inc.

HLS Therapeutics

Formed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages.

Tuesday, April 30th

1:30pm; Hall CD

TSX-V: HLS

PRESENTING COMPANIES



ImmunoPrecise Antibodies

ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials. ImmunoPrecise operates from state-of-the-art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia, in collaboration with its wholly-owned subsidiary operations at U-Protein Express B.V., in the Life Science Incubator, Utrecht, and ModiQuest Research, Oss, both in the Netherlands. The Company operates globally to offer antibody services from target analysis to pre-clinical studies.

Wednesday, May 1st

2:00pm; Hall CD

TSX-V: IPA



IMMUNOVACCINE

IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company's proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV's lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck.

Wednesday, May 1st

11:00am; Hall B

TSX: IMV



IntelGenx

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. IntelGenx's highly skilled team provides comprehensive pharmaceutical services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients.

Tuesday, April 30th

2:30pm; Hall B

TSX-V: IGX NASDAQ: IGXT



Intellijoint Surgical

Intellijoint Surgical® develops and commercializes surgical navigation solutions. Intellijoint's flagship product, Intellijoint HIP® provides surgeons with real-time, intraoperative measurements to ensure proper size selection and positioning of orthopaedic implants during total hip replacements. Intellijoint is committed to improving patients' lives by providing every surgeon with effective, easy-to-use technology. Intellijoint Surgical is the recipient of the North American Frost & Sullivan Enabling Technology Leadership Award, the Futurpreneur Shopify True Grit Award and the Growing Strong Futurpreneur Award.

Tuesday, April 30th

10:00am; Hall A

Private

PRESENTING COMPANIES



Interface Biologics

Interface Biologics (IBI) is an early commercial stage, privately held company that develops innovative materials for Medtech and Pharmaceutical applications. IBI surface modification additives are used in FDA-approved medical devices and are clinically proven to reduce infection and thrombus-related complications. IBI's sustained local drug delivery technology is applicable across a range of drug classes and medical specialties with an initial focus on ophthalmology.

Wednesday, May 1st

10:30am; Hall A

Private



Kneat

Kneat develops and markets the next generation Kneat Gx software platform. Multiple business processes can be configured on the platform from equipment to computer system validation, through to production record execution and quality document management. Kneat Gx allows users to author, review, approve, execute testing online, manage any exceptions and post approve final deliverables in a controlled FDA 21 CFR Part 11/ Eudralex Annex 11 compliant platform. Macro and micro report dashboards enable powerful oversight into all systems, projects and processes world wide. Customer case studies are reporting productivity improvements in excess of 100% and a higher compliance standard.

Wednesday, May 1st

11:30am; Hall A

Private



Knight Therapeutics

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD.

Tuesday, April 30th
9:30am; Hall CD

TSX: GUD



LED Medical Diagnostics

LED Medical Diagnostics Inc. is a dental imaging technology provider focused on delivering state-of-the-art imaging software and systems. Through its wholly-owned subsidiaries LED Dental Inc., LED Dental Ltd., and Aptyeryx, Inc., LED Medical provides dentists and oral health specialists with advanced diagnostic imaging devices and software. LED's proprietary technologies include the VELscope Vx Enhanced Oral Assessment and TUXEDO Intraoral Sensors, in addition to Aptyeryx's XrayVision, XVWeb and XrayVision DCV imaging software solutions.

Wednesday, May 1st
11:00am; Hall A

TSX-V: LMD

PRESENTING COMPANIES



Medexus Pharmaceuticals

Medexus, a direct subsidiary of Pediapharm, is a Canadian specialty pharmaceutical company focused on the licensing, registration, marketing, sales and distribution of innovative pharmaceutical products in Canada, with strategic partnerships in key international markets. Medexus has a strong position in the Canadian marketplace and focuses on key growth areas with an emphasis on rheumatology as well as women's health and dermatology. The healthcare solutions offered by Medexus include: Metoject®, Oralvisc®, Tricovel®, Multi-Gyn®, Calcia®, IronOne®, Monoderma A-C-E-M™, Allergoff® and Triamcinolone Hexacetonide.

Tuesday, April 30th

11:00am; Hall CD

Private



Medicenna Therapeutics

Medicenna is a clinical stage immunotherapy company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines™ (ECs). Our mission is to become the leader in the development and commercialization of ECs and Superkines for the treatment of a broad range of cancers and immune-mediated diseases. MDNA55 is Medicenna's lead EC currently enrolling in a multi-centre Phase 2 clinical trial for the treatment of recurrent glioblastoma (rGBM), the most common and uniformly fatal form of brain cancer. MDNA55 has secured Orphan Drug Status from the United States Food and Drug Administration (FDA) and the European Medicines Agency as well as Fast Track Designation from the FDA for the treatment of rGBM.

Tuesday, April 30th

2:00pm; Hall B

TSX: MDNA



Medicure

Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAG™ (pitavastatin) tablets and the ReDS™ device in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc.

Tuesday, April 30th
10:30am; Hall CD

TSX-V: MPH



Methapharm

Methapharm is a specialty pharmaceutical company that focuses on the development, acquisition, licensing, and promotion of healthcare products in North America. Methapharm markets its own proprietary products as well as partners with global companies in order to deliver a line of products in the USA and Canada.

Wednesday, May 1st
3:30pm; Hall A

Private

PRESENTING COMPANIES



Microbix Biosystems

Microbix specializes in developing proprietary biological and technology solutions for human health and well-being. It manufactures a wide range of critical biological materials for the global diagnostics industry, notably antigens used in immunoassays or quality assessment products. Microbix's products are sold to more than 100 customers worldwide, primarily to multinational diagnostics companies and laboratory accreditation organizations.

Tuesday, April 30th
4:00pm; Hall B

TSX: MBX



Mimi's Rock

Mimi's Rock is a diverse, global group of health and business professionals dedicated to offering you a wide selection of wellness products that we are proud to stand behind. We are committed to exceeding our customers' expectations, while aiding them in improving their overall wellness. When you feel better, you live better and that is our promise to you.

Wednesday, May 1st
1:30pm; Hall A

Private



NeuPath Health

Providing world class patient care since 2005, CPM plays an important role in filling a growing need for community-based pain services in the Canadian healthcare system. With 9 clinics across Ontario - from London to Ottawa - CPM Centres for Pain Management is the largest chronic pain management group in Canada. The vast majority of our services are covered by OHIP and our physicians and healthcare professionals focus on interventional treatment of chronic pain.

Wednesday, May 1st
3:00pm; Hall CD

Private



Newtopia

Newtopia is a personalized health company dedicated to inspiring individuals to make the right lifestyle decisions to live healthy. Newtopia's health engagement approach leverages genetics, the latest engagement science and personality matched coaching to build highly personalized lifestyle plans that deliver sustainable results. Newtopia's programs and products are guideline and evidence-based and are available across the United States and Canada.

Tuesday, April 30th
9:30am; Hall A

Private

PRESENTING COMPANIES



Nuvo Pharmaceuticals

Nuvo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company targets several therapeutic areas, including pain, allergy and dermatology. The Company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Nuvo's head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the U.S. Food and Drug Administration (FDA), Health Canada and E.U. approved manufacturing facility is located in Varennes, Québec, Canada.

Tuesday, April 30th
2:00pm; Hall CD

TSX: NRI



Oncolytics Biotech

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype - turning "cold" tumors "hot" - through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer.

Tuesday, April 30th
11:00am; Hall B

TSX: ONC NASDAQ: ONCY



Opsens

Opsens focuses mainly on the measure of FFR and dPR in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a 2nd-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 50,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.

Tuesday, April 30th

2:30pm; Hall A

TSX: OPS



Precision NanoSystems

Precision NanoSystems Inc (PNI) creates innovative solutions for the discovery, development and manufacture of medicines and medical research. PNI's proprietary NanoAssembler Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology.

Tuesday, April 30th

11:00am; Hall A

Private

PRESENTING COMPANIES



Profound Medical

The Profound Medical team is committed to creating the powerful combination of real-time MR-guidance as the imaging platform, and ultrasound as the energy source for delivering non-invasive ablative tools to clinicians. These key technology pillars, linked with intelligent software and robotics, have the potential to fulfill unmet needs of patients and clinicians in many anatomies and disease states, including prostate cancer, uterine fibroids, and bone metastases. Our mission is to profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate tissue with precision; a tomorrow where patients have access to safe and effective treatment options, so they can quickly return to their daily lives.

Tuesday, April 30th

3:30pm; Hall A

TSX-V: PRN



Repair Therapeutics

Repair Therapeutics is pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in clearly defined patient populations. The company's initial focus is on novel targeted therapies in cancer types harboring defective DNA-damage response (DDR)- or genome instability-related functions. Repair's SNIPRx™ platform combines a proprietary, high throughput, CRISPR-enabled gene editing target discovery technology with high-resolution protein crystallography, computational biology, medicinal chemistry and clinical informatics to rapidly generate small molecules for clinical investigation. The company is backed by leading global healthcare investors including Versant Ventures and MPM Capital.

Wednesday, May 1st

2:00pm; Hall B

Private



Satellos Bioscience

Satellos Bioscience is a private, Canadian-based regenerative medicine company formed in 2018 as a partnership among Dr. Michael Rudnicki, one of the country's foremost stem cell scientists and CEO of the Stemcell Network of Canada, Bloom Burton & Co. - the nation's largest healthcare investment bank -- and Mr. Frank Gleeson, a serial biotech entrepreneur and former healthcare VC. Satellos has recently completed a seed round of financing to pursue its unique approach of pharmacologically modulating stem cell polarity to stimulate in vivo tissue repair and regeneration. Our initial focus is muscle regeneration, a field in which Dr. Rudnicki is a world leader, with a lead program in Duchenne Muscular Dystrophy.

Wednesday, May 1st

2:30pm; Hall B

Private



Searchlight Pharma

Searchlight Pharma Inc., headquartered in Montreal, aspires to become a leading Canadian-based specialty healthcare company through best-in class execution of the search, acquisition, commercialization, and focused development of innovative and unique specialty healthcare products that improve life-long human health and wellness. With a core focus on women's health, urology, and pediatrics, our team is committed to improving people's lives by bringing the right products to market.

Wednesday, May 1st

3:00pm; Hall A

Private

PRESENTING COMPANIES



Sernova Corp

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body.

Wednesday, May 1st

4:00pm; Hall CD

TSX-V: SVA



Shoppers Drug Mart

Shoppers Drug Mart Corporation is one of the most recognized and trusted names in Canadian retailing. The Company is the licensor of full-service retail drug stores operating under the name Shoppers Drug Mart (Pharmaprix in Québec). With almost 1,300 Shoppers Drug Mart and Pharmaprix stores operating in prime locations in each province and two territories, the Company is one of the most convenient retailers in Canada. The Company also licenses or owns 47 medical clinic pharmacies operating under the name Shoppers Simply Pharmacy (Pharmaprix Simplement Santé in Québec) and three luxury beauty destinations operating as Murale. In addition to its retail store network, the Company owns Shoppers Drug Mart Specialty Health Network Inc., a provider of specialty drug distribution, pharmacy and comprehensive patient support services, and MediSystem Technologies Inc., a provider of pharmaceutical products and services to long-term care facilities. Shoppers Drug Mart is an independent operating division of Loblaw Companies Limited.

Wednesday, May 1st

11:30am; Hall CD

Private



STEMCELL Technologies

STEMCELL Technologies supports life sciences research with more than 2,500 specialized reagents, tools, and services. We offer high quality cell culture media, cell separation technologies, instruments, accessory products, and educational resources that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally.

Wednesday, May 1st
1:30pm; Hall CD

Private



Synaptive Medical

Synaptive Medical Inc., a Toronto-based medical device and technology company, designs hardware and software that cross traditional barriers in hospitals and improve patient care delivery in and beyond the operating room. Synaptive's Modus V™ and integrated BrightMatter™ solutions—including surgical planning, navigation and visualization, and an informatics platform—give leading clinicians and healthcare systems the right information they need to ensure the best possible outcomes for patients.

Tuesday, April 30th
2:00pm; Hall A

Private

PRESENTING COMPANIES



Think Research

Think Research, a leading digital healthcare platform provider, today announced enhanced capabilities in delivering evidence-based clinical content to Cerner Millennium customers through Cerner PowerPlans, Care Sets, and Patient Care Plans. For years, Think Research has brought value to various Electronic Health Record (EHR) platforms through its Entrypoint application as well as through delivery directly into Computerized Physician Order Entry (CPOE) systems.

Wednesday, May 1st
9:30am; Hall A

Private



Titan Medical

Titan Medical Inc. is focused on computer-assisted robotic surgical technologies for application in MIS. The Company is developing the SPORT Surgical System, a single-port robotic surgical system comprised of a surgeon-controlled patient cart that includes a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures, and a surgeon workstation that provides an advanced ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body. Titan intends initially to pursue focused surgical indications for the SPORT Surgical System, which may include one or more of gynecologic, urologic, colorectal or general abdominal procedures.

Tuesday, April 30th
1:30pm; Hall A

TSX: TMD



Trillium Therapeutics

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company's two clinical programs, TTI-621 and TTI-622, target CD47, a "do not eat" signal that cancer cells frequently use to evade the immune system. Trillium also has a proprietary fluorine-based medicinal chemistry platform that is being used to develop novel compounds directed at undisclosed immuno-oncology targets.

Tuesday, April 30th

9:30am; Hall B

TSX: TRIL NASDAQ: TRIL



Triumvira Immunologics

Triumvira Immunologics, Inc. (Triumvira) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, our corporate offices are in Austin, Texas, and our research facilities in Hamilton, Ontario.

Wednesday, May 1st

3:00pm; Hall B

Private

PRESENTING COMPANIES



TSO3

Founded in 1998, TSO3's activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. TSO3 also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.

Tuesday, April 30th
3:00pm; Hall A

TSX: TOS



VALEO PHARMA™

Valeo Pharma

Valeo Pharma is a specialty pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada. With a focus on neurodegenerative diseases, woman's health and oncology, Valeo Pharma has a growing portfolio of innovative products and the proper infrastructure to manage these products through all stages of commercialization. Headquartered in Kirkland, Quebec, Valeo Pharma has all the internal capabilities to register and market health care solutions for Canadian patients.

Wednesday, May 1st
4:00pm; Hall A

CSE: VPH



VieMed

VieMed, through its indirect wholly-owned subsidiaries Sleep Management, L.L.C. and Home Sleep Delivered, L.L.C., is a home medical equipment supplier that provides post-acute respiratory care services in the United States. Sleep Management, L.L.C. focuses on disease management and improving the quality of life for respiratory patients through clinical excellence, education, and technology. Its service offerings are based on effective home treatment with respiratory care practitioners providing therapy and counseling to patients in their homes using cutting edge technology. Home Sleep Delivered focuses on providing in-home sleep testing for sleep apnea sufferers.

Wednesday, May 1st

2:30pm; Hall CD

TSE: VMD



WELL Health Technologies

WELL is a unique company that operates Primary Healthcare Facilities as well as a significant EMR or Electronic Medical Records business that supports the digitization of such clinics. WELL's overarching objective is to empower primary care doctors to provide the best and most advanced care possible leveraging the latest trends in digital health. In the last 12 months, WELL physicians served approximately 600,000 patient visits through its network of 19 medical clinics. WELL is publicly traded on the Exchange under the symbol WELL.V. WELL Health Technologies was recognized as a TSX Venture 50 Company in 2018 and 2019.

Wednesday, May 1st

3:30pm; Hall CD

TSX-V: WELL

PRESENTING COMPANIES



Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc. is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.

Wednesday, May 1st

10:00am; Hall B

NASDAQ: XENE



Zymeworks

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. The Company's suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, ZW25, is a novel Azymetric™ bispecific antibody currently in a Phase 1 clinical trial. The Company's second clinical candidate, ZW49, is a bispecific antibody-drug conjugate in a Phase 1 clinical trial and combines the unique design and antibody framework of ZW25 with Zymeworks' proprietary ZymeLink™ cytotoxic payload. Zymeworks is also advancing a deep preclinical pipeline in immunology and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through multiple strategic partnerships with eight global biopharmaceutical companies.

Tuesday, April 30th

10:00am; Hall B

TSX: ZYME NASDAQ: ZYME

Public Companies

Acerus Pharmaceuticals
Aequus Pharmaceuticals
Antibe Therapeutics
Aptose Biosciences
Aurinia Pharmaceuticals
Avivagen
BELLUS Health
BioSyent Pharma
Centric Health
Cipher Pharmaceuticals
Correvio Pharma
Crescita Therapeutics
CRH Medical
ESSA Pharma
Hamilton Thorne
HLS Therapeutics
ImmunoPrecise Antibodies
IMV
IntelGenx
Knight Therapeutics
LED Medical Diagnostics
Medicenna Therapeutics
Medicure
Microbix Biosystems
Nuvo Pharmaceuticals
Oncolytics Biotech
Opsens
Profound Medical
Sernova Corp
Titan Medical
Trillium Therapeutics
TSO3
Valeo Pharma
Viemed
WELL Health Technologies
Xenon Pharmaceuticals
Zymeworks

Private Companies

7D Surgical
AbCellera
Appili Therapeutics
Conavi Medical
Dot Health
Endoceutics
Eupraxia Pharmaceuticals
Exact Imaging
Fusion Pharmaceuticals
Greenbrook TMS
Grey Wolf Animal Health
Highland Therapeutics
Intellijoint Surgical
Interface Biologics
Kneat
Medexus
Methapharm
Mimi's Rock
NeuPath Health
Newtopia
Precision NanoSystems
Repare Therapeutics
Satellos Bioscience
Searchlight Pharma
Shoppers Drug Mart
STEMCELL Technologies
Synaptive Medical
Think Research
Triumvira Immunologics

keynote speaker

BRAD LONCAR
Loncar Investments

MAY 1ST
8:30 AM



keynote SPEAKER

Brad Loncar is an independent biotechnology investor and CEO of Loncar Investments, a firm that specializes in the creation of thematic biotechnology investment indexes. Its first two products are The Cancer Immunotherapy Index

BRAD LONCAR

and The China BioPharma Index. Mr. Loncar previously worked in the financial services industry at Franklin Templeton Investments, where he was a member of the Management Training Program, and was appointed to serve in a Senior Advisor role at the U.S. Department

of the Treasury. He currently writes biotechnology commentary at www.LoncarBlog.com and has contributed opinion pieces to Endpoints News and Xconomy.com. He is one of the most followed commentators in biotech on social media. With a focus on oncology, Loncar Investments is an official charitable partner of the Cancer Research Institute.



panelists

Our panelists are recognized industry leaders who have made worthwhile contributions to the healthcare sector globally.

- **April 30th:** Investing in Commercial-Stage Healthcare Companies
- **May 1st:** Investing in R&D-Stage Healthcare Companies





SUMNER ANDERSON

As a Partner on the Pharmaceuticals team at Deerfield, Sumner provides extensive research and analysis on individual companies operating in the healthcare industry. Sumner joined Deerfield in 2012 from Millennium Management, where he was a research analyst covering pharmaceuticals. Prior to Millennium, Sumner was a Managing Director in healthcare investment banking at Wells Fargo Securities and a pharmaceutical analyst in Global Equities at Citadel Investment Group. Sumner's

healthcare investment career has been split between investment banking and equity long short funds. Sumner holds an A.B. in History and Economics from Harvard University, and he earned his M.B.A. with an emphasis in finance and accounting at New York University.

CECILIA GONZALO

Ms. Gonzalo is a Partner at Oberland Capital. Prior to joining Oberland, she was a Managing Director at Vatera Healthcare Partners where she focused on venture capital and private equity investments in the biopharmaceutical industry. Previously, Ms. Gonzalo was a Managing Director with Essex Woodlands, a healthcare-focused growth equity firm. Ms. Gonzalo previously worked for 12 years in the healthcare group of Warburg Pincus LLC, a global private equity firm. Prior to her tenure at Warburg Pincus, Ms. Gonzalo worked at Goldman, Sachs & Co as an Analyst in the firm's Investment Banking Division and Principal Investment Area. Ms. Gonzalo currently serves as a board member and Co-President of the Harvard Business School Healthcare Alumni Association. Ms. Gonzalo earned an A.B. in Biochemical Sciences from Harvard College and an M.B.A. from Harvard Business School.





ADELE OLIVA

Adele Oliva has been a healthcare investor for over 20 years and focuses on commercial stage medical technology, healthcare service, and specialty pharmaceutical investments. Adele co-founded 1315 Capital in 2014 to establish a firm focused on healthcare growth investing and the firm has since raised two funds and has over \$500 million under management. She was recruited to Quaker Partners in 2007 to expand their growth stage investing practice. Prior to Quaker, Adele was Co-Head of US Healthcare at Apex Partners, where she started in 1997. Forbes recognized Adele on its Midas List of top 100 technology investors worldwide, top 10 life science investors, and top women in venture capital. In 2016, Adele was recognized by the Philadelphia Business Journal as part of the Power 76 list of the region's most influential people. Prior to entering private equity as a Kauffman Fellow, Adele held roles at CoreStates and Baxter Healthcare. Adele received a BSc from St. Joseph's University and an MBA from Cornell University, where she was awarded the Albert Fried Fellowship. Adele has served on the board of Ascent Healthcare Solutions (acquired by Stryker), EKR Therapeutics (acquired by Cornerstone Therapeutics), ESP Pharma (acquired by Protein Design Labs), Esprit Pharma (acquired by Allergan), Genoptix (acquired by NeoGenomics), Precision Dermatology (acquired by Valeant), Prometheus Labs (acquired by Nestle), and SkinMedica (acquired by Allergan). She currently serves on the boards of Colorescience, Encore Dermatology, Innovative Health, NovaSom, Onkos Surgical, and TELA Bio.

JASON WILD

Jason Wild is the President and Chief Investment Officer of JW Asset Management, LLC, the advisor for three investment partnerships. Mr. Wild received his license as a pharmacist in 1997, and subsequently founded JW Asset Management, LLC in 1998. The firm has a strong history of finding opportunities within the specialty pharmaceutical sector. He is a graduate of the Arnold and Marie Schwartz College of Pharmacy where he received a bachelor's degree in Pharmacy.



CHRIS YORK

Chris York is Co-Head of MidCap's Life Sciences & Technology Finance Group. Mr. York brings more than 19 years of experience providing venture debt financing to private and public technology and life science companies. Mr. York was one of the founding members of the Merrill Lynch Capital Life Sciences Venture Debt team. Prior to Merrill Lynch Capital, Mr. York spent 6 years at Silicon Valley Bank where he was responsible for developing and maintaining

relationships with venture capital and private equity firms throughout the East Coast. Prior to joining Silicon Valley Bank, Mr. York was a professional golfer for 2 years, playing on various professional tours throughout the world. Mr. York graduated from Georgetown University in Washington, D.C. with a B.S. in Finance.



JEREL DAVIS

Jerel Davis, Ph.D., is a Managing Director based in Vancouver, Canada. Since joining Versant in 2011, he has been involved in launching and investing in a number of Versant's portfolio companies including Quanticel (sale), Novira (sale), Crispr (2016 IPO), Inception 4 (sale), Inception 5 (sale), Northern, Turnstone, BlueRock, Repare, VenatoRx and Akero. He has led Versant's execution of creative corporate transactions with multiple pharmaceutical

partners including Celgene, Roche and Bayer, and was instrumental in establishing Versant's presence in Canada, including the creation of our company-building infrastructure in Vancouver, Toronto and Montreal. Jerel was promoted to Managing Director at Versant in 2015. Prior to joining Versant, Jerel was an Associate Principal at McKinsey and Company where he advised healthcare corporations in pharmaceuticals, biotechnology, medical device and molecular diagnostics. He has worked in a number of healthcare markets globally including the U.S., Canada, Europe, China, Russia and India. Jerel was a post-doctoral fellow at Stanford University, where he also completed his Ph.D., and trained at Amgen as a researcher.

ARJUN GOYAL

Arjun Goyal is a Co-Founder and Managing Director of Vida Ventures.

From 2014 through 2017, Arjun was an investment professional at 5AM Ventures, a life science focused venture firm. Arjun was a Board Observer at Aprea AB, Spyryx, Pear Therapeutics, Portal Instruments, Entrada, and Homology Medicines (NASDAQ: FIXX). At 5AM Ventures, Arjun was part of the founding team of Homology Medicines, a genetic medicines company and he also served as Acting VP of



PANEL: Investing in R&D-Stage Healthcare Companies

Business Development at Pear Therapeutics. Prior to joining 5AM Ventures, Arjun was Co-Founder and CEO, Foresight Pharmaceuticals, a biopharmaceutical company developing hormonal treatments for infectious diseases.

Arjun received his B.S. in Medical Science, Diploma in French and his M.D. degree from the Universities of Melbourne and Oxford. He completed his postgraduate medical training in Internal Medicine at the University of Sydney. He received his M.Phil. in Bioscience Enterprise from Cambridge on a Commonwealth Scholarship and his MBA from Harvard Business School. Arjun has received several awards for his work including the American Australian Association Education Fellowship, Robert Kaplan Life Science Fellowship, Oxford Clarendon Scholarship, Gates Cambridge Scholarship and Reg Waite Award for Young Australians. He is a co-inventor on one patent and has served on the editorial board of an international scientific journal.

Arjun is a Board Observer at Pionyr Immunotherapeutics and serves on the Committee for the American Australian Association Education Fellowship and LifeTech Advisory Board of the Swedish American Chamber of Commerce, and was on the 2016 NCI Review Committee for SBIR grants.

TING JIA

Dr. Ting Jia, also known as TJ, Ph.D., is Managing Partner of Octagon Advisors. Prior, Dr. Jia served as a Managing Director at Hillhouse Capital Management, where he was primarily responsible for managing the firm's public and private investments in the life science sector. Prior to that, he worked as an investment analyst at BVF Partners LP and as a management consultant at McKinsey & Company. He received his Ph.D. in Immunology from Weill Cornell and Memorial Sloan-Kettering Cancer Center, and a B.S. in Biological Sciences from Sun Yat-sen University.





DORON JUNGER

A surgeon by background, Doron Junger MD has for the past 15 years managed public equity portfolios of biotechnology and pharmaceutical companies for some of the world's largest hedge funds, including Citadel (2003-2005), S.A.C. (2006-2007) and Millennium Partners (2017-2018), as well as J.P. Morgan (2007-2009). He also co-founded the NYC-based healthcare hedge fund Pura Vida Investments, and managed its flagship therapeutics portfolio while helping to grow its assets under management by over tenfold (2012-2017). Doron fuses his knowledge of medicine and finance to carefully diligence profitable long and short biopharmaceutical investment opportunities. Based in Miami Beach, Florida, Doron originally started Sanvia Capital as a Millennium platform company. Dr. Junger earned degrees from Oxford University in Physiological Sciences in 1991 and in Medicine in 1994. Between 1994 and 1998 he completed his basic surgical training in London and became a Fellow of the Royal College of Surgeons of England in 1998. He passed the United States Medical Licensure Examinations Steps 1, 2 and 3, and in 1995 was awarded the certificate of the Educational Commission for Foreign Medical Graduates. After receiving an MBA from INSEAD in Fontainebleau, France in 1999, he began his finance career in healthcare investment banking at Credit Suisse. Doron is fluent in English, German and French, and is currently learning Hebrew. He lives in Miami Beach with his wife and two daughters.

MAHA KATABI

Maha joined Sofinnova as a Partner in 2019. She focuses on development stage investments in therapeutics.

Prior to joining Sofinnova, Maha was a Managing Partner of Oxalis Capital. She is an experienced investor in biopharma companies, with over 18 years in venture capital investing and public equities portfolio management. Prior to founding Oxalis in 2018, Maha was a Partner at Sectoral Asset Management since 2008, where she formed and led a dedicated investment team and advisory board to drive investments in private companies. Additionally, she was a Portfolio Manager for a family of funds, that invested in publicly listed and private healthcare companies. Prior to Sectoral, Maha was Vice-President at Ventures West Management since 2004, a venture capital firm focusing on technology and life sciences in Canada and the United States. She started her venture capital career in 1999 at T2C2 Capital Bio, a seed fund focused on Canadian start-ups.

Maha received her PhD in Pharmacology and BSc in Biology from McGill University, and is a CFA charterholder. She is currently Chair of the board of Exactis Innovation, an oncology precision medicine network, and serves on the board of BIOQuébec, an industry association active in the healthcare sector in Canada.





sponsors

We gratefully acknowledge our sponsors who support our vision for the Canadian healthcare sector.



**Baker
McKenzie.**

b | **Berkley**
CANADA
| a Berkley Company

Blakes

BLG
Borden Ladner Gervais

 **CDRD**

Deloitte.


EY
Building a better
working world

 **FORTUITY.**

 **MARSH**

**mccarthy
tetrault**

 **NORTON ROSE FULBRIGHT**

RICHARDSONGMP
ROSEMARY HORWOOD
WEALTH

TMX THE FUTURE
IS YOURS TO SEE.

TORYS
LLP

troutman
sanders

W&R
Wilson Sonsini Goodrich & Rosati
PROFESSIONAL CORPORATION



**BLOOM BURTON & CO.
HEALTHCARE INVESTOR
CONFERENCE**

COCKTAIL RECEPTION

APRIL 30TH
5:00pm - 9:00pm

Steam Whistle Brewing
255 Bremner Blvd.



CO
CK
TAIL
RECEPTION

Bloom Burton & Co.

The Bloom Burton team has been dedicated exclusively to the healthcare investment industry for more than a decade.

We speak with large companies and investors every day, and we know what they are looking for. We are therefore the ideal group to help our companies plan their capital market strategies, investigate the relevance of new biological pathways, and consider new therapeutic indications and clinical designs, catalogue and diligence new products or companies for acquisition.



We identify the most
impactful companies for
our investor network and
we provide tailor-made
support solutions for
management and Boards of
healthcare companies.



services

Our services help identify,
cultivate and create
investment opportunities
in the healthcare sector on
behalf of companies and
investors.

From start-ups through commercial launches, we are active in all areas of the healthcare industry, including biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, healthcare IT, life science tools, animal health, nutrition and wellness.

Our seven business services work cohesively to accelerate monetization for both company and investor clients.



Raising Capital & Financing

Sourcing capital to fund healthcare opportunities

M&A Advisory

Enabling monetization through strategic transactions

Equity Research

Influential opinions and insights on companies

Sales & Trading

Generating returns for investors

Monetization Planning

Helping realize the value of innovations

Direct Investment

Maximizing opportunities in healthcare investing

Company Creation

Establishing new opportunities in healthcare



「 At Bloom Burton &
Co., we serve investors
and companies seeking
to make meaningful
change to the
healthcare industry. 」

The people who work at Bloom Burton have deep knowledge in medicine, science, patent and corporate law, finance and healthcare invention, development and commercialization.

our methodology

As a result of our expertise and experience in healthcare, we have developed a disciplined methodology for helping companies grow faster.

Our methodology, and all of the services we offer, rest on six key pillars: deeper due diligence, a broader range of investment options, greater understanding of cross-border rules, relationships with international investors, engagement with the broader healthcare community, and a creative, tenacious, entrepreneurial culture.

We never blame “market conditions” or approach transactions as a “numbers game.”

Our long-term commitment to each investor and company challenges us to continuously refine our strategies until we achieve success. We are creative in our approach to financing and growth, and tenacious in finding the right transaction for all parties.

logistics

COMPANY
PRESENTATIONS

HALL 104 A, B, CD

ONE-ON-ONE
MEETINGS

HALL 105

KEYNOTE AND
PANEL DISCUSSIONS


HALL 106/107

WiFi ACCESS

Bloom Burton & Co.

ACCESS CODE

BBHIC2019



BLOOM BURTON
AWARD GALA

THURSDAY, SEPTEMBER 26TH, 2019

FOUR SEASONS HOTEL

60 YORKVILLE AVENUE

BLACK TIE GALA

COCKTAILS 6:00 PM

DINNER 7:00 PM



bloom burton & co

/accelerating returns in healthcare